[
    [
        {
            "time": "2018-03-01",
            "original_text": "复星医药(02196.HK)：因任期届满 汪群斌、张学庆及韦少琨辞任非执行董事 董监高成员变化",
            "features": {
                "keywords": [
                    "复星医药",
                    "董监高",
                    "辞任",
                    "非执行董事"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)：因任期届满 汪群斌、张学庆及韦少琨辞任非执行董事 董监高成员变化",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-15",
            "original_text": "复星医药(02196.HK)累计对外担保金额约131.72亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "对外担保",
                    "金额"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)累计对外担保金额约131.72亿元",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-20",
            "original_text": "复星医药(02196.HK)：集团续展及新增委托贷款/借款额度不超80亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "委托贷款",
                    "借款额度"
                ],
                "sentiment_score": -0.1,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)：集团续展及新增委托贷款/借款额度不超80亿元",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-08-30",
            "original_text": "复星医药(600196.SH)2018年营收249.18亿元 研发投入升63.92%至25.07亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "营收",
                    "研发投入",
                    "增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)2018年营收249.18亿元 研发投入升63.92%至25.07亿元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-10",
            "original_text": "复星医药对外投资暨关联交易公告",
            "features": {
                "keywords": [
                    "复星医药",
                    "对外投资",
                    "关联交易"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药对外投资暨关联交易公告",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-25",
            "original_text": "复星医药(02196.HK)拟斥2.55亿元与复星健控增资复拓生物",
            "features": {
                "keywords": [
                    "复星医药",
                    "增资",
                    "复拓生物"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)拟斥2.55亿元与复星健控增资复拓生物",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-12-15",
            "original_text": "复星医药：2018年净利润同比减13.33%，拟10派3.2元 盈利能力下降",
            "features": {
                "keywords": [
                    "复星医药",
                    "净利润",
                    "下降",
                    "分红"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药：2018年净利润同比减13.33%，拟10派3.2元 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-12-20",
            "original_text": "医疗保健：创新型药企有望迎来估值重塑 荐4股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "创新型药企",
                    "估值重塑"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "创新药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医疗保健：创新型药企有望迎来估值重塑 荐4股",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-01-05",
            "original_text": "平安证券：带量采购进入落地阶段，把握细分龙头结构性机会",
            "features": {
                "keywords": [
                    "平安证券",
                    "带量采购",
                    "落地",
                    "细分龙头"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "政策"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "平安证券：带量采购进入落地阶段，把握细分龙头结构性机会",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-01-10",
            "original_text": "生物医药行业周报:带量采购进入落地阶段,把握细分龙头结构性机会",
            "features": {
                "keywords": [
                    "生物医药",
                    "带量采购",
                    "落地",
                    "细分龙头"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技",
                    "政策"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "生物医药行业周报:带量采购进入落地阶段,把握细分龙头结构性机会",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]